• Product NameLGI1 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAffinity chromatography purified via peptide column
• ApplicationsELISA WB IHC
• Species ReactivityHu Ms Rt
• SpecificityThis LGI1 antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a 14 amino acid peptide from near the center of human LGI1.
• Target NameLGI1
• Alternative Names    Leucine-rich, glioma inactivated 1, epitempin, EPT
• Accession No. Swiss-Prot:O95970
  Gene ID:9211
• UniprotO95970
• Gene ID9211;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form.

• Western blot analysis of LGI1 in HeLa cell lysate with LGI1 antibody at 2 ug/mL.
• Immunohistochemical staining of human brain tissue using LGI1 antibody at 2.5 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting